This announcement is a separate document:
アステラス製薬：抗体-薬物複合体パドセブ 根治切除不能な尿路上皮癌に対する一次治療としてのペムブロリズマブとの併用療法について日本で適応追加に関する承認を取得
Astellas Pharma: Antibody-drug complex Padceb obtains approval for additional indications in Japan for combination therapy with pembrolizumab as primary treatment for unresectable urothelial cancer
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated